Handelsbanken Fonder AB Raises Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Handelsbanken Fonder AB raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 23.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,100 shares of the company's stock after purchasing an additional 7,700 shares during the period. Handelsbanken Fonder AB's holdings in Hims & Hers Health were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Blume Capital Management Inc. raised its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the period. Smartleaf Asset Management LLC raised its holdings in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth approximately $38,000. UMB Bank n.a. raised its holdings in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after buying an additional 933 shares during the period. Finally, US Bancorp DE raised its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after buying an additional 1,508 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Melissa Baird sold 33,333 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the transaction, the chief operating officer now directly owns 805,083 shares of the company's stock, valued at approximately $20,755,039.74. This represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael Chi sold 5,600 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $57.00, for a total value of $319,200.00. Following the transaction, the insider now directly owns 256,380 shares of the company's stock, valued at approximately $14,613,660. The trade was a 2.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 628,067 shares of company stock valued at $25,832,688. 13.71% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Truist Financial dropped their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a report on Thursday, April 10th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $61.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Citigroup reissued a "sell" rating and set a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $38.00.

Hims & Hers Health Stock Down 3.2%

HIMS traded down $1.82 during trading on Friday, reaching $55.33. 26,342,229 shares of the company were exchanged, compared to its average volume of 21,156,056. The company's 50-day moving average is $45.09 and its two-hundred day moving average is $38.21. The company has a market cap of $12.38 billion, a price-to-earnings ratio of 125.75 and a beta of 2.09. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 110.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.05 EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.